Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on Novemb...(in the later stages of Phase 2 clinical ...),Health

Date:11/4/2008

in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

'/>"/>

SOURCE Orexigen Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Arno Therapeutics Appoints William F. Hamilton to Board of Directors
4. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
5. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
6. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
7. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
8. Synvista Therapeutics Appoints William Federici to its Board of Directors
9. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
10. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes